ClinicalTrials.gg
CompletedNCT03965052PRO-179/IUpdated Dec 12, 2019Results posted

Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®

A Phase 1 interventional study of PRO 179 and Travatan 0.004 % Ophthalmic Solution in Glaucoma, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-12.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.

Enrollment
34th of 39
24 · median 89
Started
2019
with 1 other
Phase 1
Only one
of the 42
Registered
41st of 42
by date
Lead sponsor
1 of 42
Laboratorios Sophia S.A de C.V.

Among the 42 studies testing travoprost in Glaucoma, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 1, and was the 41st registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing travoprost in Glaucoma as a file.
02

Study summary

Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.

Goals: To evaluate the safety and tolerability of the formulation PRO-179 manufactured by Sophia Laboratories S.A. of C.V. on the ocular surface of clinically healthy subjects.

Hypothesis:The ophthalmic solution PRO-179 presents a profile of safety and tolerability similar to Travatan® in healthy subjects.

Methodology: Clinical trial Phase I, controlled, of parallel groups, double blind, with randomization.

Read the detailed description

Number of patients: n= 24, 12 subjects per group (both eyes). Main inclusion criteria: Clinically healthy subjects.

duration: 10 days.

Duration of subject in the study: 15 to 22 days.

Adverse events will be reported and cataloged based on the MedDRA dictionary and will be reported to the corresponding regulatory entity.

The sponsor will carry out monitoring or quality visits to the research sites where it corroborates the information of the source documents and will contrast them with the information presented in the electronic CRF. Electronic case report forms will be evaluated by the clinical research associate and the clinical team of the sponsor (medical ophthalmologist researcher and pharmacologist of clinical safety).

Statistical methodology:

The data will be expressed with measures of central tendency: mean and standard deviation for the quantitative variables. The qualitative variables will be presented in frequencies and percentages. The statistical analysis will be carried out by means of the Mann-Whitney U test for the quantitative variables for the difference between the groups. The difference between the qualitative variables will be analyzed by means of X2 (Chi2) or Fisher's exact. An alpha ≤ 0.05 will be considered significant.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • Travoprost
  • ophthalmic solution
  • Prostaglandin Analogues
  • Antiglaucoma drugs
  • glaucoma
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be clinically healthy.
  • Have the ability to give their signed and show willingness to comply with the study procedures
  • Have an age between 18 to 45 years.
  • Indistinct sex.
  • Women should ensure the continued use of a hormonal method or intrauterine device (IUD) during the study period.
  • Present blood tests: within normal parameters or with a range of ± 20% as long as the subject is clinically healthy.

Blood count (BH): , erythrocytes, hematocrit, total leukocytes, , mean corpuscular volume and mean corpuscular hemoglobin.

  • Blood chemistry of three elements (QS): Glucose, urea and creatinine.
  • Liver function tests (PFH): and Alanine Aminotransferase, total , direct and indirect.

    • Present visual ability 20/30 or better in both eyes.
    • Present vital signs within normal parameters.
    • Present intraocular pressure ≥10 and ≤ 21 mmHg.

Exclusion criteria

Exclusion Criteria:

  • Be a user of topical ophthalmic products of any kind.
  • Be a user of medicines, or herbal products, by any other route of administration, with the exception of hormonal in the case of women.
  • In case of being a woman, being pregnant or breastfeeding.
  • Have participated in clinical research studies 90 days prior to inclusion in the present study.
  • Have previously participated in this same study.
  • Be a user of contact lenses and can not suspend their use during the study.
  • That they can not follow the lifestyle considerations described in section 6.2.2
  • Having started the use of hormonal contraceptives or IUD, 30 days prior to inclusion in the present study.
  • Having a history of any chronic-degenerative disease.
  • Present inflammatory or infectious disease, active at the time of admission to the study.
  • Present injuries or unresolved traumas at the time of entering the study.
  • Having the antecedent of any type of eye surgery.
  • Having undergone surgical procedures, not ophthalmological, in the last 3 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    PRO-179

    Dosage: 1 drop every 24 hours, at night, in both eyes.

    Drug: PRO 179

  • Active comparator
    Travatan®

    Dosage: 1 drop every 24 hours, at night, in both eyes.

    Drug: Travatan 0.004 % Ophthalmic Solution

Interventions

  • * Generic name: Travoprost * Distinctive denomination: Bristrio® (PRO-179) * Active principles: Travoprost 0.004%. * Pharmaceutical form: Ophthalmic solution * Presentation: multi-dose dropper bottle, 2.5 milliliters. * Prepared by: Sophia Laboratories, S.A. of C.V. * Description of the solution: transparent solution, free of visible particles. * Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.

    Also known as: PRO-179, Bristrio®, Travoprost 0.004% ophthalmic solution

  • * Generic name: Travoprost * Distinctive denomination: Travatan® * Active ingredients: Travoprost 0.004% * Pharmaceutical form: Ophthalmic solution. * Presentation: multi-dose dropper bottle, 2.5 milliliters. * Prepared by: Alcon Laboratories Inc. * Description of the solution: transparent solution, free of visible particles. * Consult information to prescribe.

    Also known as: Travoprost 0.004% ophthalmic solution

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent. it will be evaluated by the number of reported cases per group.

    Time frame: during the 14 days of evaluation, including the safety call (day 14).

  2. Eye Comfort Index

    It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).

    Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)

Secondary outcomes

  1. Number of Eyes With Epithelial Defects by Grade

    The epithelial defects will be evaluated by means of two stains, lissamine green and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.

    Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)

  2. Visual Ability

    The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and the worst vision is 20/200, higher values represent a worst vision. The result of the Snellen chart has equivalents in an international logarithmic system called Logmar (logarithm of the minimum angle of resolution) for better understanding. Snellen Scale: 20/200, 20/100, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10. Snellen / LogMAR equivalences: 20/200= 1.0, 20/100=0.7, 20/50=0.4, 20/40=0.3, 20/30=0.2, 20/25=0.1, 20/20=0.0, 20/15=0.13, 20/12=0.2, 20/10=-0.3, etc.

    Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)

  3. Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade

    Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.

    Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)

  4. Number of Eyes of Chemosis

    The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.

    Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)

Other outcomes

  1. Changes in Intraocular Pressure

    the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg

    Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)

07

Results

Posted Dec 12, 2019

Participant flow

Participant flow — Overall Study
MilestonePRO-179Travatan®
Started1212
Completed1112
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryNumber of Participants With Adverse Events

primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent. it will be evaluated by the number of reported cases per group.

Time frame:
during the 14 days of evaluation, including the safety call (day 14).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPRO-179Travatan®
Number of Participants With Adverse Events1011
Statistical analysis
  • PRO-179 vs Travatan® · Fisher Exact · p = 1.000
PrimaryEye Comfort Index

It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).

Time frame:
will be evaluated at the end of the treatment, at the final visit (day 11)
Reported as:
Mean · score on a scale
Eye Comfort Index
score on a scalePRO-179Travatan®
Eye Comfort Index26.61 ± 11.328.97 ± 7.9
SecondaryNumber of Eyes With Epithelial Defects by Grade

The epithelial defects will be evaluated by means of two stains, lissamine green and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.

Time frame:
will be evaluated at the end of the treatment, at the final visit (day 11)
Reported as:
Count of units · eyes
Number of Eyes With Epithelial Defects by Grade
eyesPRO-179Travatan®
Green lissamine grade 02223
Green lissamine grade 101
Green lissamine grade 200
Green lissamine grade 300
Green lissamine grade 400
Fluorescein grade 02020
Fluorescein grade 124
Fluorescein grade 200
Fluorescein grade 300
Fluorescein grade 400
Statistical analysis
  • PRO-179 vs Travatan® · Fisher Exact · p = 1.000
  • PRO-179 vs Travatan® · Fisher Exact · p = 0.667
SecondaryVisual Ability

The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and the worst vision is 20/200, higher values represent a worst vision. The result of the Snellen chart has equivalents in an international logarithmic system called Logmar (logarithm of the minimum angle of resolution) for better understanding. Snellen Scale: 20/200, 20/100, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10. Snellen / LogMAR equivalences: 20/200= 1.0, 20/100=0.7, 20/50=0.4, 20/40=0.3, 20/30=0.2, 20/25=0.1, 20/20=0.0, 20/15=0.13, 20/12=0.2, 20/10=-0.3, etc.

Time frame:
will be evaluated at the end of the treatment, at the final visit (day 11)
Reported as:
Mean · LogMAR
Visual Ability
LogMARPRO-179Travatan®
Visual Ability0.0 ± 00.0 ± 0
Statistical analysis
  • PRO-179 vs Travatan® · Wilcoxon (Mann-Whitney) · p = 1.000
SecondaryPercentage of Eyes With Conjunctival Hyperemia (CH) by Grade

Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.

Time frame:
will be evaluated at the end of the treatment, at the final visit (day 11)
Reported as:
Count of units · eyes
Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade
eyesPRO-179Travatan®
Normal (0)1416
Very mild (1)22
Mild (2)66
Moderate (3)00
Severe (4)00
Statistical analysis
  • PRO-179 vs Travatan® · Chi-squared, Corrected · p = 0.977
SecondaryNumber of Eyes of Chemosis

The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.

Time frame:
will be evaluated at the end of the treatment, at the final visit (day 11)
Reported as:
Count of units · eyes
Number of Eyes of Chemosis
eyesPRO-179Travatan®
Number of Eyes of Chemosis00
Other pre-specifiedChanges in Intraocular Pressure

the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg

Time frame:
will be evaluated at the end of the treatment, at the final visit (day 11)
Reported as:
Mean · mmHg
Changes in Intraocular Pressure
mmHgPRO-179Travatan®
Changes in Intraocular Pressure11.95 ± 1.610.71 ± 1.5
Statistical analysis
  • PRO-179 vs Travatan® · Wilcoxon (Mann-Whitney) · p = 0.019

Adverse events

Collected over Adverse events were evaluated for about 2 months and one week until the last follow-up call of the last subject.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRO-1790/12 (0%)1/12 (8.3%)10/12 (83.3%)
Travatan®0/12 (0%)0/12 (0%)11/12 (91.7%)
Most frequent serious events
Most frequent serious events
EventPRO-179Travatan®
ocular hypotonyEye disorders1/120/12
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPRO-179Travatan®
red eyeEye disorders10/129/12
ocular burningEye disorders4/126/12
Dry eyeGeneral disorders4/123/12
eye itchingEye disorders2/123/12
eye painEye disorders2/122/12
photophobiaEye disorders2/121/12
tearingEye disorders0/122/12
headacheNervous system disorders0/121/12
eyelid painEye disorders0/121/12
ocular hypotonyEye disorders1/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)PRO-179Travatan®Total
Mean28.2 ± 8.024.7 ± 4.626.3 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)PRO-179Travatan®Total
Female4812
Male8412
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PRO-179Travatan®Total
Latin121224
Region of Enrollment
Region of Enrollment(participants)PRO-179Travatan®Total
Mexico121224
08

Study locations

1 site
  • Jose Navarro Partida
    Guadalajara, Jalisco 45160, Mexico
09

References and documents

Publications

  • Munoz-Villegas P, Navarro-Sanchez AA, Sanchez-Rios A, Olvera-Montano O, Baiza-Duran LM. Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials. Ther Clin Risk Manag. 2021 Oct 21;17:1123-1134. doi: 10.2147/TCRM.S331294. eCollection 2021. PubMed 34707360 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jul 2019, 2 months.

Results were first posted in Dec 2019, 5 months after primary completion.

Of 18 phase 1 interventional studies under Glaucoma, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2019
First posted
May 28, 2019
StartActual
Apr 24, 2019
Primary completionActual
Jul 2, 2019
CompletionActual
Aug 29, 2019
Results first posted
Dec 12, 2019
Last update
Dec 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03965052
Responsible party
Sponsor
First posted
May 28, 2019
Start date
Apr 24, 2019
Primary completion
Jul 2, 2019
Completion
Aug 29, 2019
Results posted
Dec 12, 2019
Last update
Dec 12, 2019

Study contacts

Leopoldo Baiza Durán, MD
study director · Laboratorios Sophia S.A de C.V.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion